Combination of Pioglitazone and Metformin Actions on Liver Lipid Metabolism in Obese Mice

3-tert-Butyl-4-hydroxyanisole Impairs Hepatic Lipid Metabolism in Male Mice Fed with a High-Fat Diet

(2022) Zhendong Sun et al.   ENVIRONMENTAL SCIENCE & TECHNOLOGY

Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis

(2022) Charlotte J Green et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Metformin treatment rescues CD8+ T cell response to immune checkpoint inhibitor therapy in mice with NAFLD

(2022) Simon Wabitsch et al.   JOURNAL OF HEPATOLOGY

Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms

(2022) Hager H. Shaaban et al.   LIFE SCIENCES

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

(2022) Dongmei Wang et al.   Frontiers in Pharmacology

Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning

(2022) Cheng Zhang et al.   EBioMedicine

Cadmium perturbed lipid profile and induced liver dysfunction in mice through phosphatidylcholine remodeling and promoting arachidonic acid synthesis and metabolism

(2022) Jie Gu et al.   ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY

Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study

(2022) Kuang-Hua Huang et al.   Frontiers in Endocrinology

How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?

(2021) Yana Geng et al.   Hepatology International

Non-alcoholic fatty liver disease

(2021) Elizabeth E Powell et al.   LANCET

FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption

(2021) Bethan L. Clifford et al.   Cell Metabolism

Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity

(2021) Samuel M Lee et al.   ENDOCRINOLOGY

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease

(2021) Fasiha Kanwal et al.   GASTROENTEROLOGY

Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus

(2021) Daniel Ferguson et al.   Nature Reviews Endocrinology

Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease

(2021) Jennifer R. Kramer et al.   HEPATOLOGY

Association of FADS1/2 Locus Variants and Polyunsaturated Fatty Acids With Aortic Stenosis

(2020) Hao Yu Chen et al.   JAMA Cardiology

Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific Manner

(2020) Karthickeyan Chella Krishnan et al.   Cellular and Molecular Gastroenterology and Hepatology

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021

(2020)   DIABETES CARE

Combination of metformin and genistein alleviates non-alcoholic fatty liver disease in high-fat diet-fed mice

(2020) Fahimeh Zamani-Garmsiri et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

(2020) Daniel Q. Huang et al.   Nature Reviews Gastroenterology & Hepatology

Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function

(2019) Zhengtao Liu et al.   METABOLIC ENGINEERING

Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway

(2019) Xiaopeng Zhu et al.   FREE RADICAL BIOLOGY AND MEDICINE

The gut microbiota promotes hepatic fatty acid desaturation and elongation in mice

(2018) Alida Kindt et al.   Nature Communications

Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish

(2018) Sofia de Oliveira et al.   JOURNAL OF HEPATOLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Sphingolipids and glycerophospholipids – The “ying and yang” of lipotoxicity in metabolic diseases

(2017) S. Rodriguez-Cuenca et al.   PROGRESS IN LIPID RESEARCH

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

(2015) Michal Pawlak et al.   JOURNAL OF HEPATOLOGY

Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate

(2015) Agnieszka Zwolak et al.   PLoS One

Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin

(2013) Morgan D Fullerton et al.   NATURE MEDICINE

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

(2011) E. Boettcher et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents

(2011) Joel E. Lavine   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Increased Diacylglycerols Characterize Hepatic Lipid Changes in Progression of Human Nonalcoholic Fatty Liver Disease; Comparison to a Murine Model

(2011) D. Lee Gorden et al.   PLoS One

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

(2010) Giovanni Musso et al.   HEPATOLOGY